Yujiro Hata, Ideaya Biosciences CEO
Ideaya outlines regulatory path for rare eye cancer drug after positive mid-stage data
Ideaya Biosciences has set the stage on what a Phase 3 trial would look like for its rare eye cancer drug darovasertib, after reporting positive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
